(Source: AbbVie Inc) - Interim results from the independent AMBER study demonstrated 98 percent (n=39/40) SVR(12) rate in patients who completed a 12- or 24-week treatment regimen and 12 weeks follow-up - Real world interim data presented at the Viral Hepatitis Congress supports findings from previous HCV genotype 1 Phase 3 clinical trials with VIEKIRAX + EXVIERA NORTH CHICAGO, Illinois , Sept. 11, 2015 /PRNewswire / -- New real world interim data from the independent AMBER study were presented for AbbVie's VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) with or without ribavirin (RBV) in genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients....
↧